Literature DB >> 29792896

Exploring new treatment paradigms for alcoholic hepatitis by extrapolating from NASH and cholestasis.

Thoetchai Bee Peeraphatdit1, Douglas A Simonetto1, Vijay H Shah2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29792896      PMCID： PMC6258016          DOI： 10.1016/j.jhep.2018.05.012

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  18 in total

1.  Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.

Authors:  Vlad Ratziu; Stephen A Harrison; Sven Francque; Pierre Bedossa; Philippe Lehert; Lawrence Serfaty; Manuel Romero-Gomez; Jérôme Boursier; Manal Abdelmalek; Steve Caldwell; Joost Drenth; Quentin M Anstee; Dean Hum; Remy Hanf; Alice Roudot; Sophie Megnien; Bart Staels; Arun Sanyal
Journal:  Gastroenterology       Date:  2016-02-11       Impact factor: 22.682

2.  Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification.

Authors:  Sung-Min Ahn; Se Jin Jang; Ju Hyun Shim; Deokhoon Kim; Seung-Mo Hong; Chang Ohk Sung; Daehyun Baek; Farhan Haq; Adnan Ahmad Ansari; Sun Young Lee; Sung-Min Chun; Seongmin Choi; Hyun-Jeung Choi; Jongkyu Kim; Sukjun Kim; Shin Hwang; Young-Joo Lee; Jong-Eun Lee; Wang-Rim Jung; Hye Yoon Jang; Eunho Yang; Wing-Kin Sung; Nikki P Lee; Mao Mao; Charles Lee; Jessica Zucman-Rossi; Eunsil Yu; Han Chu Lee; Gu Kong
Journal:  Hepatology       Date:  2014-09-22       Impact factor: 17.425

3.  Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats.

Authors:  Len Verbeke; Ricard Farre; Jonel Trebicka; Mina Komuta; Tania Roskams; Sabine Klein; Ingrid Vander Elst; Petra Windmolders; Tim Vanuytsel; Frederik Nevens; Wim Laleman
Journal:  Hepatology       Date:  2014-04-14       Impact factor: 17.425

4.  A decrease in fasting FGF19 levels is associated with the development of non-alcoholic fatty liver disease in obese adolescents.

Authors:  Malgorzata Wojcik; Dominika Janus; Katarzyna Dolezal-Oltarzewska; Anna Kalicka-Kasperczyk; Karolina Poplawska; Dorota Drozdz; Krystyna Sztefko; Jerzy B Starzyk
Journal:  J Pediatr Endocrinol Metab       Date:  2012       Impact factor: 1.634

Review 5.  Alcoholic hepatitis: current challenges and future directions.

Authors:  Ashwani K Singal; Patrick S Kamath; Gregory J Gores; Vijay H Shah
Journal:  Clin Gastroenterol Hepatol       Date:  2013-06-28       Impact factor: 11.382

Review 6.  Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases.

Authors:  Harmeet Malhi; Michael Camilleri
Journal:  Curr Opin Pharmacol       Date:  2017-11-05       Impact factor: 5.547

Review 7.  IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice.

Authors:  Jan Petrasek; Shashi Bala; Timea Csak; Dora Lippai; Karen Kodys; Victoria Menashy; Matthew Barrieau; So-Yun Min; Evelyn A Kurt-Jones; Gyongyi Szabo
Journal:  J Clin Invest       Date:  2012-09-04       Impact factor: 14.808

8.  Prednisolone or pentoxifylline for alcoholic hepatitis.

Authors:  Mark R Thursz; Paul Richardson; Michael Allison; Andrew Austin; Megan Bowers; Christopher P Day; Nichola Downs; Dermot Gleeson; Alastair MacGilchrist; Allister Grant; Steven Hood; Steven Masson; Anne McCune; Jane Mellor; John O'Grady; David Patch; Ian Ratcliffe; Paul Roderick; Louise Stanton; Nikhil Vergis; Mark Wright; Stephen Ryder; Ewan H Forrest
Journal:  N Engl J Med       Date:  2015-04-23       Impact factor: 91.245

9.  A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.

Authors:  Frederik Nevens; Pietro Andreone; Giuseppe Mazzella; Simone I Strasser; Christopher Bowlus; Pietro Invernizzi; Joost P H Drenth; Paul J Pockros; Jaroslaw Regula; Ulrich Beuers; Michael Trauner; David E Jones; Annarosa Floreani; Simon Hohenester; Velimir Luketic; Mitchell Shiffman; Karel J van Erpecum; Victor Vargas; Catherine Vincent; Gideon M Hirschfield; Hemant Shah; Bettina Hansen; Keith D Lindor; Hanns-Ulrich Marschall; Kris V Kowdley; Roya Hooshmand-Rad; Tonya Marmon; Shawn Sheeron; Richard Pencek; Leigh MacConell; Mark Pruzanski; David Shapiro
Journal:  N Engl J Med       Date:  2016-08-18       Impact factor: 91.245

10.  Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease.

Authors:  Svanhildur Haflidadottir; Jon G Jonasson; Helga Norland; Sylvia O Einarsdottir; David E Kleiner; Sigrun H Lund; Einar S Björnsson
Journal:  BMC Gastroenterol       Date:  2014-09-27       Impact factor: 3.067
View more
  3 in total

Review 1.  Highlights From the AASLD/EASL ALD Endpoints Conference 2019.

Authors:  Madeline Bertha; Haripriya Maddur
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-06-30

Review 2.  New insights into the bile acid-based regulatory mechanisms and therapeutic perspectives in alcohol-related liver disease.

Authors:  Yali Liu; Tao Liu; Xu Zhao; Yanhang Gao
Journal:  Cell Mol Life Sci       Date:  2022-08-17       Impact factor: 9.207

Review 3.  Severe alcoholic hepatitis: current perspectives.

Authors:  Cyriac Abby Philips; Philip Augustine; Praveen Kumar Yerol; Sasidharan Rajesh; Pushpa Mahadevan
Journal:  Hepat Med       Date:  2019-08-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.